Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ANGLE part of consortium that will set set standard for identifying cancer

CANCER-ID is backed by €14mln of funding and involves 38 companies and institutions from 13 countries across Europe.
ANGLE part of consortium that will set set standard for identifying cancer
Parsortix is able to detect tiny cancer cells in the blood

ANGLE PLC (LON:AGL, OTCQX:ANPCY) is part of a Europe-wide consortium that will set the standards for using blood-based markers to identify cancer.

The AIM-listed company will contribute its Parsortix technology, which harvests circulation tumour cells (CTC) that identify the presence and particular strain of the killer disease.

The CANCER-ID programme in which it is taking part will assess whether the ANGLE device should provide the standard method of harvesting CTCs.

Running until 2020, an initial evaluation will be followed by a clinical phase to establish the use of liquid biopsies in treating lung and breast cancer. 

This is intended to provide clinical evidence to support the adoption of liquid biopsy in routine cancer care.

CANCER-ID is backed by €14mln of funding and involves 38 companies and institutions from 13 countries across Europe, including German giant Bayer and Italy’s Menarini Silicon Biosystems.

Andrew Newland, ANGLE’s founder and chief executive, said: “We are delighted to be part of this programme as it offers the Parsortix system the potential to be specified as a standard CTC harvesting system for clinical use in patients with lung cancer and breast cancer in Europe, with the opportunity for collaboration with multiple downstream analysis companies."

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

hepatitisC.jpg
July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use